Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
November-2017 Volume 16 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2017 Volume 16 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism

  • Authors:
    • Yu Yang
    • Jicheng Tantai
    • Yifeng Sun
    • Chenxi Zhong
    • Zhigang Li
  • View Affiliations / Copyright

    Affiliations: Department of Thoracic Surgery, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200030, P.R. China
    Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 6483-6488
    |
    Published online on: September 11, 2017
       https://doi.org/10.3892/mmr.2017.7453
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Hyperoside (HY) is a major pharmacologically active component from Prunella vulgaris L. and Hypericum perforatum. The present study aimed to determine the anticancer effect of HY and determine the underlying mechanisms involved. Human A549 cells were treated with HY (10, 50 and 100 µM), and cell viability was detected by an MTT assay. Cell apoptosis and mitochondrial membrane potential were determined by flow cytometry. Western blot analysis was used to identify the expression of apoptosis‑associated proteins and phosphorylation of MAPK. The present study demonstrated that HY significantly inhibited the viability of A549 cells in a time‑ and dose‑dependent manner, and enhanced the percentage of apoptotic cells. HY also significantly increased the protein phosphorylation of p38 mitogen‑activated protein kinase (MAPK) and c‑Jun N‑terminal kinase (JNK), disrupted mitochondrial membrane penetrability, and triggered the release of mitochondrial cytochrome c and apoptosis‑inducing factor into the cytosol. Treatment with HY also activated the expression of caspase‑9 and caspase‑3. These results suggested that HY‑induced apoptosis was associated with activation of the p38 MAPK‑ and JNK‑induced mitochondrial death pathway. HY may offer potential for clinical applications in treating human non‑small cell lung cancer and improving cancer chemotherapy.

Introduction

Lung cancer, characterized by high incidence and mortality rates, is a malignant tumor, which threatens human health. It is reported that the incidence and mortality rates have increased significantly in several countries in the last 50 years (1,2). The etiology of lung cancer remains to be fully elucidated, and there is substantial data showing a close association between long-term heavy smoking and the occurrence of lung cancer (2). Non-small cell lung cancer (NSCLC) accounts for ~80% of all lung cancer cases, and ~75% of patients are diagnosed in the middle-late stage (3,4). Therapies for NSCLC include surgery, radiation and chemotherapy; however, the 5-year survival rate remains low. In addition, the side effects and pain from treatment cause substantial physical and mental trauma to patients. In previous years, the screening of compounds from medicinal plants for the treatment of various diseases has received increased attention. For example, the anticancer drug, paclitaxel (Taxol), obtained from Taxus species has been extensively investigated for several years (5). Therefore, obtaining anticancer compounds from medicinal plants is important in cancer treatment.

Hyperoside (HY; Fig. 1) is a major pharmacologically active component from Prunella vulgaris L. and Hypericum perforatum, which exerts a wide variety of biological activities, including antioxidant, antihyperglycemic, anticancer, anti-inflammatory and cardiovascular protective effects (6–9). However, the underlying molecular mechanisms remain to be fully elucidated. The present study aimed to determine the anticancer effect of HY and identifying the possible mechanism involved. In the present study, HY was identified as an anticancer agent, which induced the apoptosis of human NSCLC A549 cells though the mitochondria apoptotic pathway.

Figure 1.

Chemical structure of hyperoside.

Materials and methods

Cell culture

A549 cells were obtained from the Shanghai Cell Bank, Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin, and incubated in a humidified atmosphere at 37°C with 5% CO2.

HY preparation

HY with a purity of 98.78% was obtained as a canary yellow needle-shaped crystal (YUANYE Technological Co. Ltd., Shanghai, China). It was dissolved in an appropriate volume of dimethylsulfoxide (DMSO) and diluted to the desired concentrations (10, 50 and 100 µM) prior to utilization, with the final concentration of DMSO maintained below 0.5%.

Cell viability

A standard tetrazolium bromide (MTT) assay was used to assess cell viability. Briefly, the cells (5×103 cells/well) were seeded in 96-well plates. Following treatment with HY (0, 10, 50 and 100 µM) for 24 h at 37°C, 50 ml of MTT (Sigma-Aldrich; Merck Millipore, Darmstadt, Germany) solution (2 mg/ml in PBS) was added to each well and the plates were incubated for an additional 4 h at 37°C. The medium was then removed and the cells were incubated with 200 µl DMSO in the dark for 30 min at 37°C to dissolve violet crystals. The absorbance was read at 570 nm on an automatic microplate reader with DMSO as the blank control. All assays were performed with five replicates and repeated at least three times.

Cell apoptosis

In order to determine cell apoptosis, 5×104 cells were trypsinized, washed with cold phosphate-buffered saline (PBS) and resuspended in binding buffer according to the manufacturer's protocol of the Annexin V-fluorescein isothiocyanate (FITC)/propidium iodide (PI) Apoptosis Detection kit (cat. no. KGA106; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). FITC-Annexin V and PI were added to the fixed cells for 20 min in darkness at room temperature. Subsequently, Annexin V binding buffer was added to the mixture prior to quantifying the fluorescence using a FACSort flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Cell apoptosis was analyzed using Cell Quest version 3.0 (BD Biosciences).

Mitochondrial membrane potential (MMP)

Rhodamine-123 (Rho-123) dye (Sigma-Aldrich; Merck Millipore) was used to detect alterations in MMP. The cells (5×104 cells/well) were cultured in a 24-well plate. Following treatment with HY (0, 10, 50 and 100 µM) for 24 h, the cells were washed with PBS, incubated with Rho-123 (10 mg/ml) for 30 min at 37°C and subsequently subjected to flow cytometry.

Separation of mitochondrial and cytosolic fractions

A mitochondria/cytosol fractionation kit (Abcam, Cambridge, UK) was used to prepare the mitochondrial and cytosolic fractions from the cells, in accordance with the manufacturer's protocol. Following treatment for 12 h with the different concentrations of HY, the cells were harvested, washed by PBS and centrifuged at 600 × g for 5 min at 4°C. Following re-suspension with cytosolic extraction buffer, the cells were homogenized on ice for 40 passes with a grinder for 10 min. The homogenate was subsequently centrifuged at 700 × g for 10 min at 4°C, supernatant was carefully collected, and the sediment was saved. Following centrifugation at 10,000 × g for 30 min at 4°C, the supernatant was collected as the cytosolic fraction and stored at −80°C. The sediment was re-suspended with mitochondrial extraction buffer, vortexed and stored as the mitochondrial fraction at −80°C.

Western blot analysis

The cultured cells were harvested and washed twice with PBS, and lysed in ice-cold radioimmunoprecipitation assay buffer (Beyotime Institute of Biotechnology, Shanghai, China) with freshly added 0.01% protease inhibitor cocktail (Sigma-Aldrich; Merck Millipore) and incubated on ice for 30 min. The cell lysate was centrifuged at 13,000 × g for 10 min at 4°C, following which the supernatant was run on a 10% SDS-PAGE gel and transferred electrophoretically onto a polyvinylidene fluoride membrane (EMD Millipore, Billerica, MA, USA). The blots were blocked with 5% skim milk, followed by incubation with antibodies against phosphorylated (P)-c-Jun N-terminal kinase (P-JNK; cat. no. ab4821; 1:500; Abcam), JNK (cat. no. ab154902; 1:200; Abcam), P-P38 (cat. no. ab47363; 1:500; Abcam), P38 (cat. no. ab170099; 1:1,000; Abcam), GAPDH (cat. no. ab9485; 1:2,500; Abcam), apoptosis-inducing factor (AIF; cat. no. ab1998; 1:500; Abcam), cytochrome c (cat. no. ab13575; 1:500; Abcam), caspase-3 (cat. no. ab2171; 1:500; Abcam) and caspase-9 (cat. no. ab32539, 1:1,000; Abcam) at 4°C overnight. The blots were then incubated with goat anti-mouse or anti-rabbit secondary antibody (Beyotime Institute of Biotechnology, Shanghai, China) at room temperature for 1 h and visualized using SuperSignal West Dura Extended Duration substrate (Thermo Fisher Scientific, Inc.) and detected using a DNR Bio-Imaging System (DNR Bio-Imaging Systems, Ltd., Jerusalem, Israel). Protein density levels were determined by Image Analysis software version 4.0.3.2 (Scion Co., Ltd., Frederick, MD, USA) and the densitometric analysis of blots from three experiments.

Statistical analysis

All results are presented as the mean ± standard deviation and the data were analyzed using the SPSS 13.0 statistical package (SPSS, Inc., Chicago, IL, USA). Data for multiple comparisons were subjected to one-way analysis of variance followed by Dunnett's test. P<0.05 was considered to indicate a statistically significant difference.

Results

HY suppresses the viability of A549 cells

Following treatment of the cells with various concentrations of HY (0, 10, 50 and 100 µM) for 12, 24 and 48 h, cell viability was determined using an MTT assay. As shown in Fig. 2, HY inhibited the viability of the A549 cells in a time- and dose-dependent manner. Cell proliferation was markedly decreased, compared with that in the control group.

Figure 2.

HY inhibits the proliferation of A549 cells. Following treatment with HY (10, 50 and 100 µM) for 12, 24 and 48 h, cell viability was detected using tetrazolium bromide. Data are presented as the mean ± standard deviation (n=6). **P<0.01, compared with the control group. HY, hyperoside; OD, optical density.

HY induces the apoptosis of cells

In order to quantify cellular apoptosis, a flow cytometric assay was performed to analyze the proportion of apoptotic cells dyed with PI and Annexin V, to enable evaluation of the integrity of cell membrane and the externalization of phosphatidylserine. As shown in Fig. 3, analysis of the cell population revealed distinct sets within the population. The majority of cells were alive in the control group (Fig. 3). However, when the cells were incubated with various concentrations of HY for 24 h, there was a notable increase in the percentage of apoptotic cells, and this occurred in a dose-dependent manner.

Figure 3.

HY induces apoptosis of human A549 cells. The A549 cells were treated with HY (0, 10, 50 and 100 µM) for 24 h and cell apoptosis was assessed using flow cytometry. Data are presented as the mean ± standard deviation (n=6). **P<0.01, compared with the control group. HY, hyperoside. The lower left quadrant shows viable cells, which are negative for both AV and PI. The lower right quadrant displays early apoptotic cells, which are positive for AV and negative for PI. The upper right quadrant represents late apoptotic cells, which are positive for both AV and PI. The upper left quadrant indicates the cells damaged during the procedure. AV, Annexin V; PI propidium iodide.

HY enhances MMP dissipation

The fluorescent intensity (FI) of Rho123 is positively correlated with the MMP. As shown in Fig. 4, high intensity fluorescence was visible in the control group of cells. Following HY treatment for 24 h, FI decreased in a dose-dependent manner.

Figure 4.

HY enhances MMP dissipation. MMP was identified by the fluorescent intensity of rhodamine 123 following treatment with HY (0, 10, 50 and 100 µM) treatment for 24 h. Data was presented as the mean ± standard deviation (n=6). **P<0.01, compared with the control group. HY, hyperoside; MMP, mitochondrial membrane potential.

HY induces the release of cytochrome c and AIF

Following MMP dissipation, the key event of mitochondria-dependent apoptosis is the release of mitochondrial cytochrome c and AIF into cytosol. Therefore, these two parameters were evaluated using western blot analysis. The results revealed that the expression levels of cytochrome c and AIF (Fig. 5A) were lower in the control group of cells, and were significantly elevated by HY treatment for 24 h.

Figure 5.

Effects of HY on the protein expression of Cyt c, AIF, caspase-3 and caspase-9. (A) A549 cells treated with HY (0, 10, 50 and 100 µM) for 12 h. The cytosolic fractions of cells were prepared and the protein expression of levels of Cyt c and AIF were analyzed using western blot analysis, with GAPDH used as a loading control. (B) Expression levels of caspase-3 and caspase-9 were detected using western blot analysis. Data are presented as the mean ± standard deviation (n=3). **P<0.01, compared with the control group. HY, hyperoside; Cyt c, cytochrome c; AIF, apoptisis-inducing factor.

HY activates caspase-3 and caspase-9

Caspase-3, a common downstream apoptosis effector, can be activated by caspase-9 or caspase-8 and cleaved into the active fragment. In the present study, the protein expression levels of caspase-3 and caspase-9 were detected using western blot analysis. The expression levels of caspase-3 and caspase-9 in the control group were low (Fig. 5B). However, treatment with HY for 12 h elevated their expression levels in a dose-dependent manner.

HY facilitates protein phosphorylation of p38 mitogen-activated protein kinase (MAPK) and JNK

Cell apoptosis is closely associated with activation of the JNK and p38 MAPK signaling pathways, which is characterized by increased protein phosphorylation of p38 MAPK and/or JNK. Following treatment with HY for 3 h, the protein phosphorylation levels of p38 MAPK and JNK were analyzed using western blot analysis (Fig. 6A and B). Treatment with HY for 3 h increased the protein phosphorylation of p38 MAPK and JNK, and there were significant differences between the HY-treated groups and the control group.

Figure 6.

HY inhibits JNK and p38 signaling. A549 cells were treated with HY (10, 50, and 100 µM) for 3 h. Protein levels of (A) P-JNK, JNK, (B) P-p38 and p38 were identified using western blot analysis. GAPDH was used as a loading control. Data are presented as the mean ± standard deviation (n=3). *P<0.05, **P<0.01, compared with the control group. HY, hyperoside; JNK, and c-Jun N-terminal kinase; P-, phosphorylated.

Discussion

Higher plants produce an abundance of substances, which have been a reliable source of pharmaceuticals. In the present study, it was found that HY effectively inhibited the proliferation of human NSCLC A549 cells in a dose- and time-dependent manner. Furthermore, Annexin V/PI staining revealed that treatment with HY (10, 50 and 100 µM) for 12 h increased the percentage of apoptotic cells in a dose-dependent manner. These results indicated that HY induced apoptosis of the A549 cells.

MAPK pathways are generally recognized as the signal transducers of apoptosis in tumor cells, closely associated with responses to extracellular stimuli, including small molecular compounds (10–13). It is known that the MAPK system is composed of extracellular signal-regulated kinases, JNK and p38 MAP kinase. The JNK and p38 MAPK pathways can be activated by genotoxic agents and by the cytokine-mediating stress response, inducing growth inhibition and apoptosis in the cells (14). The induction of A549 cell apoptosis by 2-methoxy-1,4-naphthoquinone (MNQ) is independent of cell cycle arrest, and is mediated by the JNK and p38 MAPK signaling pathways. These signaling pathways have been found to be stimulated by oxidative DNA damage caused by the increased generation of reactive oxygen species (ROS) in the MNQ-treated A549 cells (14). It has been reported that capsaicin induces SMMC-7721 cell apoptosis through the generation of intracellular ROS, dissipation of MMP, and activation of the JNK and p38 MAPK pathways (15). Based on the above evidence, it is clear that p38 MAPK and JNK pathways are crucial in tumor cell apoptosis. In the present study, western blot analysis was used to identify the phosphorylation of p38 MAPK and JNK. The results revealed that HY significantly increased the phosphorylation levels of p38 MAPK and JNK, indicating the simultaneous activation of these two signaling pathways.

Activation of the intrinsic mitochondrial pathway can elicit the release of several apoptotic factors, including cytochrome c and AIF, which results in mitochondrial apoptosis and activates the mitochondrial apoptotic pathway. The release of cytochrome c facilitates the formation of the apoptosome-containing adaptor, apoptotic protease-activating factor-1, and another initiator, caspase-9, in the presence of dATP, following which caspase-3 is activated leading to cell apoptosis (16,17). AIF can elicit cell apoptosis independently of the activation of caspase-3 (18). The enhanced protein expression of activated caspase-3, a downstream effector caspase, indicated that HY triggered caspase-dependent apoptosis, which can be activated by the mitochondrial apoptotic pathway and/or the death receptor pathway. The present study also found that HY facilitated the loss of MMP, and the release of cytochrome c and AIF into the cytosol, and enhanced the protein expression of caspase-9. This indicated that HY induced apoptosis of the A549 cells via the mitochondrial apoptotic pathway.

In conclusion, the present study demonstrated that HY elevated the protein phosphorylation levels of p38 MAPK and JNK, disrupted MMP, facilitated the release of cytochrome c and AIF into cytoplasm, activated capase-9 and caspase-3, and led to apoptosis of the A549 cells. As a result, HY may offer potential as a useful and beneficial natural agent against lung cancer.

Acknowledgements

The present study was supported by Scientific and Technologic Innovation Action of Shanghai Municipal Science and Technology Commission (grant no. 15401971800).

References

1 

Zhang J, Liu J, Chen J, Li X, Wu Y, Chen H, Wu W, Zhang K and Gu L: Angiotensin receptor blockers (ARBs) reduce the risk of lung cancer: A systematic review and meta-analysis. Int J Clin Exp Med. 8:12656–12660. 2015.PubMed/NCBI

2 

Qiu L, Lan L, Feng Y, Huang Z and Chen Y: Pulmonary actinomycosis imitating lung cancer on (18)F-FDG PET/CT: A case report and literature review. Korean J Radiol. 16:1262–1265. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Dong QZ, Wang Y, Tang ZP, Fu L, Li QC, Wang ED and Wang EH: Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 182:954–964. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Rao JS, Gondi C, Chetty C, Chittivelu S, Joseph PA and Lakka SS: Inhibition of invasion, angiogenesis, tumor growth and metastasis by adenovirus-mediated transfer of antisense uPAR and MMP-9 in non-small cell lung cancer cells. Mol Cancer Ther. 4:1399–1408. 2005. View Article : Google Scholar : PubMed/NCBI

5 

Yue W, Ming QL, Lin B, Rahman K, Zheng CJ, Han T and Qin LP: Medicinal plant cell suspension cultures: Pharmaceutical applications and high-yielding strategies for the desired secondary metabolites. Crit Rev Biotechnol. 36:215–232. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Ku SK, Zhou W, Lee W, Han MS, Na M and Bae JS: Anti-inflammatory effects of hyperoside in human endothelial cells and in mice. Inflammation. 38:784–799. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Sukito A and Tachibana S: Isolation of hyperoside and isoquercitrin from Camellia sasanqua as antioxidant agents. Pak J Biol Sci. 17:999–1006. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Zhang J, Zhao F, Yu X, Lu X and Zheng G: Pharmacokinetics of eupalinolide A eupalinolide B and hyperoside from Eupatorium lindleyanum in rats by LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 995–996:1–7. 2015. View Article : Google Scholar

9 

Yan Y, Feng Y, Li W, Che JP, Wang GC, Liu M and Zheng JH: Protective effects of quercetin and hyperoside on renal fibrosis in rats with unilateral ureteral obstruction. Exp Ther Med. 8:727–730. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Al-Mahdi R, Babteen N, Thillai K, Holt M, Johansen B, Wetting HL, Seternes OM and Wells CM: A novel role for atypical MAPK kinase ERK3 in regulating breast cancer cell morphology and migration. Cell Adh Migr. 9:483–494. 2015. View Article : Google Scholar : PubMed/NCBI

11 

Jung HG, Kim HH, Paul S, Jang JY, Cho YH, Kim HJ, Yu JM, Lee ES, An BJ, Kang SC and Bang BH: Quercetin-3-O-β-d-glucopyranosyl-(1→6)-β-d-glucopyranoside suppresses melanin synthesis by augmenting p38 MAPK and CREB signaling pathways and subsequent cAMP down-regulation in murine melanoma cells. Saudi J Biol Sci. 22:706–713. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Chang D, Wang YC, Bai YY, Lu CQ, Xu TT, Zhu L and Ju S: Role of P38 MAPK on MMP activity in photothrombotic stroke mice as measured using an ultrafast MMP activatable probe. Sci Rep. 5:169512015. View Article : Google Scholar : PubMed/NCBI

13 

Huo YN, Chen W and Zheng XX: ROS, MAPK/ERK and PKC play distinct roles in EGF-stimulated human corneal cell proliferation and migration. Cell Mol Biol (Noisy-le-grand). 61:6–11. 2015.PubMed/NCBI

14 

Ong JY, Yong PV, Lim YM and Ho AS: 2-Methoxy-1,4-naphthoquinone (MNQ) induces apoptosis of A549 lung adenocarcinoma cells via oxidation-triggered JNK and p38 MAPK signaling pathways. Life Sci. 135:158–164. 2015. View Article : Google Scholar : PubMed/NCBI

15 

Bu HQ, Cai K, Shen F, Bao XD, Xu Y, Yu F, Pan HQ, Chen CH, Du ZJ and Cui JH: Induction of apoptosis by capsaicin in hepatocellular cancer cell line SMMC-7721 is mediated through ROS generation and activation of JNK and p38 MAPK pathways. Neoplasma. 62:582–591. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Lee HH, Park C, Jeong JW, Kim MJ, Seo MJ, Kang BW, Park JU, Kim GY, Choi BT, Choi YH and Jeong YK: Apoptosis induction of human prostate carcinoma cells by cordycepin through reactive oxygen species-mediated mitochondrial death pathway. Int J Oncol. 42:1036–1044. 2013. View Article : Google Scholar : PubMed/NCBI

17 

Hsieh YJ, Chang CJ, Wan CF, Chen CP, Chiu YH, Leu YL and Peng KC: Euphorbia formosana root extract induces apoptosis by caspase-dependent cell death via Fas and mitochondrial pathway in THP-1 human leukemic cells. Molecules. 18:1949–1962. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Niemi NM and MacKeigan JP: Mitochondrial phosphorylation in apoptosis: Flipping the death switch. Antioxid Redox Signal. 19:572–582. 2013. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Yang Y, Tantai J, Sun Y, Zhong C and Li Z: Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism. Mol Med Rep 16: 6483-6488, 2017.
APA
Yang, Y., Tantai, J., Sun, Y., Zhong, C., & Li, Z. (2017). Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism. Molecular Medicine Reports, 16, 6483-6488. https://doi.org/10.3892/mmr.2017.7453
MLA
Yang, Y., Tantai, J., Sun, Y., Zhong, C., Li, Z."Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism". Molecular Medicine Reports 16.5 (2017): 6483-6488.
Chicago
Yang, Y., Tantai, J., Sun, Y., Zhong, C., Li, Z."Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism". Molecular Medicine Reports 16, no. 5 (2017): 6483-6488. https://doi.org/10.3892/mmr.2017.7453
Copy and paste a formatted citation
x
Spandidos Publications style
Yang Y, Tantai J, Sun Y, Zhong C and Li Z: Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism. Mol Med Rep 16: 6483-6488, 2017.
APA
Yang, Y., Tantai, J., Sun, Y., Zhong, C., & Li, Z. (2017). Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism. Molecular Medicine Reports, 16, 6483-6488. https://doi.org/10.3892/mmr.2017.7453
MLA
Yang, Y., Tantai, J., Sun, Y., Zhong, C., Li, Z."Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism". Molecular Medicine Reports 16.5 (2017): 6483-6488.
Chicago
Yang, Y., Tantai, J., Sun, Y., Zhong, C., Li, Z."Effect of hyperoside on the apoptosis of A549 human non‑small cell lung cancer cells and the underlying mechanism". Molecular Medicine Reports 16, no. 5 (2017): 6483-6488. https://doi.org/10.3892/mmr.2017.7453
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team